Compound
Inhibition of cell growth (%)
(5 μM)
MCF-7
HCT-15
BxPC-3
1a
62.4 ± 4.4
37.0 ± 7.7
33.8 ± 2.6
1b
19.9 ± 3.3
18.6 ± 0.9
10.1 ± 3.7
2a
19.7 ± 3.6
9.3 ± 3.7
17.6 ± 3.2
2b
30.1 ± 5.5
28.2 ± 5.5
33.5 ± 7.8
2c
45.5 ± 12.1
46.2 ± 9.3
15.9 ± 8.8
2d
20.9 ± 2.4
12.4 ± 4.4
15.4 ± 1.4
2e
18.7 ± 2.4
17.2 ± 1.8
12.2 ± 6.7
2f
19.7 ± 8.8
15.8 ± 4.2
3.5 ± 6.2
2g
15.4 ± 3.7
18.1 ± 3.5
10.9 ± 3.0
2h
27.1 ± 3.0
25.2 ± 5.7
15.0 ± 5.1
2i
9.4 ± 0.6
16.7 ± 5.3
2.6 ± 3.2
3f
NA
NA
NA
3g
NA
NA
NA
4a
29.0 ± 1.4
11.8 ± 3.3
42.4 ± 1.6
4b
NA
9.1 ± 4.4
NA
6d
14.0 ± 5.9
10.7 ± 1.7
3.9 ± 1.7
6e
28.3 ± 4.1
15.4 ± 1.5
9.5 ± 1.9
6f
84.5 ± 3.2
42.8 ± 3.0
28.5 ± 6.8
6g
9.1 ± 1.4
9.4 ± 6.4
NA
6h
6.9 ± 3.1
7.3 ± 2.8
NA
6i
10.8 ± 0.6
8.8 ± 6.6
NA
6l
8.6 ± 3.1
8.2 ± 2.6
NA
9d
46.5 ± 5.9
64.9 ± 7.7
32.9 ± 7.9
9e
31.5 ± 6.4
NA
23.7 ± 5.2
Doxorubicin
99.5 ± 0.3
73.6 ± 4.4
161.6 ± 5.7
Table 1:
Effect of naphthalimide compounds 1a,b, 2a-I, 3f,g, 4a,b, 6d-l, 9d,e compared to doxorubicin on the growth of MCF-7, HCT-15, and BxPC-3 human tumor cell lines.
